

## The Premier Event for Building Drug Discovery Innovations & Collaborations

**MONDAY**  
September 28

### SYMPOSIA

- Induced Proximity-Based Drug Discovery
- Generative AI/Machine Learning-Driven Drug Design

### TRAINING SEMINARS

- TS3A: AI-Driven Design of Biologics: State-of-the-Art ML Models & Real-World Applications)
- TS4A: The End Game: From Lead Optimization to Drug Candidate Selection
- TS5A: Drug Exposure at the Target: The Role of ADME and Pharmacokinetics

### SHORT COURSES

- **MORNING 9:00-11:00**  
SC1A: Protein Degradors from a Beyond-Rule-of-Five and an ADME Perspective
- **LUNCHEON WORKSHOPS 11:30-1:00**  
SC2A: Biophysical Approaches for GPCRs
- **AFTERNOON 1:30-3:30**  
SC3A: DNA-Encoded Libraries in Drug Discovery: Design, Screening, and Lead Development
- **EVENING 4:00-6:00**  
SC4A: Advanced Molecular Pharmacology for Drug Discovery: Traps, Tips, and Tricks
- **EVENING 4:00-6:00**  
SC5A: Building Agentic AI Workflows for Drug Discovery: From LLM Tools to Autonomous Discovery Pipelines
- **EVENING 4:00-6:00**  
SC6A: Best Practices for Targeting GPCRs, Ion Channels, and Transporters with Monoclonal Antibodies

### SMALL MOLECULES & PEPTIDES

#### EMERGING DRUG TARGETS

- Cancer: Degradar & Chemical Approaches
- Autoimmunity & CNS: PPI Modulators
- Obesity: Bound Peptides & Beyond

#### NOVEL DRUG MODALITIES

- PROTACs, Molecular Glues and Proximity Inducers
- Peptides, Covalent Drugs & Conjugated Therapies
- AI/ML-designed and Synthetic Biology-enabled Drug Entities

#### LEAD GENERATION STRATEGIES

- Biophysical Approaches
- GPCR-Targeted Discovery
- Library Innovations: DEL, FBDD, Covalent, D2B

#### INNOVATIVE DISCOVERY TECHNOLOGIES

- AI/ML-Enabled Target Identification and Lead Discovery
- Functional Proteomics & Genomics for Direct-to-Biology Applications
- Phenotypic and Complex In Vitro Screening and Imaging Assays

**TUESDAY** September 29 — **THURSDAY** October 1

### BIOLOGICS & RADIOLIGANDS

#### ANTIBODIES AGAINST CHALLENGING TARGETS

- AI, Structural Validation and Novel Screening
- Intelligent Modalities and Precision Engineering
- Targeting Membrane Proteins and Restrictive Barriers

#### NEXT-GENERATION CONJUGATES

- Novel Target Discovery and Validation
- Linker Chemistry and Conjugation Methods
- Emerging Payloads and Modalities

#### RADIOLIGAND THERAPIES

- Engineering Optimized Ligands, Linkers, and Radionuclides
- New Targets, Mechanisms, and Combinations
- Personalized Dosimetry and Theranostics

**TUESDAY** September 29 — **THURSDAY** October 1